ID: ALA3342366

Max Phase: Preclinical

Molecular Formula: C17H23N5

Molecular Weight: 297.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CNc1nc(NCC2CCCCC2)cc(-c2ccccn2)n1

Standard InChI:  InChI=1S/C17H23N5/c1-18-17-21-15(14-9-5-6-10-19-14)11-16(22-17)20-12-13-7-3-2-4-8-13/h5-6,9-11,13H,2-4,7-8,12H2,1H3,(H2,18,20,21,22)

Standard InChI Key:  NAQDXUQXNUZSIY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 297.41

Molecular Weight (Monoisotopic): 297.1953

AlogP: 3.57

#Rotatable Bonds: 5

Polar Surface Area: 62.73

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.46

CX LogP: 3.58

CX LogD: 3.58

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.88

Np Likeness Score: -1.10

References

1. Peukert S, Hughes R, Nunez J, He G, Yan Z, Jain R, Llamas L, Luchansky S, Carlson A, Liang G, Kunjathoor V, Pietropaolo M, Shapiro J, Castellana A, Wu X, Bose A..  (2014)  Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.,  5  (10): [PMID:25313322] [10.1021/ml500240d]

Source

Source(1):

• Scientific Literature